Leukemia, Myeloid: all 2,432 studies
Page 19 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid LeukemiaCompletedNCT01290107
- Selecting a Favorable KIR Donor in Unrelated HCT for AMLCompletedNCT01288222Not applicable
- Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus unknownNCT01280786Phase 1
- Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)CompletedNCT01279473Phase 1/2
- PET-CT in AML for Detection of Extramedullary AML ManifestationsCompletedNCT01278069
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)TerminatedNCT01265199Phase 1
- Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid LeukemiaTerminatedNCT01260714Phase 1
- A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid LeukaemiaCompletedNCT01256073Phase 1
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Patient Reported Outcomes in Chronic Myeloid LeukemiaCompletedNCT01252589
- Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal DiseaseCompletedNCT01249820Phase 2
- Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01249430Phase 1
- Biomarkers in Samples From Young Patients With Acute Myeloid LeukemiaCompletedNCT01247584
- Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)CompletedNCT01247493Phase 2
- Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CRTerminatedNCT01246752Phase 3
- Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01246622Phase 1
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world SettingCompletedNCT01244750
- Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND OptimisationCompletedNCT01243489Phase 4
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)CompletedNCT01242774Phase 1
- Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 MutationCompletedNCT01237808Phase 3
- A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.CompletedNCT01236144Phase 1/2
- Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyCompletedNCT01235572Phase 2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid LeukemiaCompletedNCT01227356Phase 2
- Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid LeukemiaTerminatedNCT01222143Phase 1/2
- Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)Status unknownNCT01221376Phase 2
- Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)CompletedNCT01220648Phase 1
- A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With ImatinibCompletedNCT01215487
- Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)Status unknownNCT01211457Phase 1/2
- AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1
- Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)CompletedNCT01203033
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT01200017
- Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)Status unknownNCT01195506
- Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 YearsTerminatedNCT01193400Phase 2
- Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AMLCompletedNCT01191957Phase 3
- RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.WithdrawnNCT01188889Phase 1/2
- Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and SurvivalStatus unknownNCT01188330Not applicable
- Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure SurveyCompletedNCT01188278
- Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHLTerminatedNCT01187810Phase 1
- Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT01180426Phase 2
- Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With AzacitidineCompletedNCT01180322Phase 2
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesCompletedNCT01175785Phase 2
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT01174888Phase 1
- PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute LeukemiasCompletedNCT01169012Phase 1
- Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)CompletedNCT01167166Phase 1/2
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AMLCompletedNCT01161550Phase 1
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01159301Phase 1
- Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSCompletedNCT01159028Phase 1
- Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01154439Phase 1
- Drug Biomarkers in Cell Samples From Patients With Acute Myeloid LeukemiaCompletedNCT01150058
- Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced LeukemiasCompletedNCT01149915Phase 1
- Decitabine Maintenance in Elderly Acute Myeloid Leukemia PatientsCompletedNCT01149408Phase 1
- Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)CompletedNCT01147939Phase 3
- Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)Status unknownNCT01146977Phase 2
- Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)Status unknownNCT01146262Phase 1/2
- Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic LeukemiaCompletedNCT01146223
- Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01146210
- Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)Status unknownNCT01145846Phase 3
- Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic LeukemiasCompletedNCT01144793
- Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid LeukemiaStatus unknownNCT01141673
- Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
- Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.TerminatedNCT01130688Phase 1
- Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid LeukemiaCompletedNCT01130662Phase 1
- Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01130506Phase 1
- Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01127009Phase 1
- A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT01126892Phase 3
- First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersCompletedNCT01120457Phase 1
- Prevention of Left Ventricular Dysfunction During ChemotherapyCompletedNCT01110824Phase 3
- ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic MalignanciesCompletedNCT01110473Phase 1
- Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid LeukemiaStatus unknownNCT01106144
- Late Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01092741Phase 2
- A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)CompletedNCT01090167Phase 1
- A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDSTerminatedNCT01085656Phase 1
- Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01076569
- Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic SyndromeCompletedNCT01075425Phase 1
- Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-AlphaTerminatedNCT01073436
- A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell TransplantationCompletedNCT01068301Phase 1
- ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)WithdrawnNCT01067274Phase 3
- A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)Status unknownNCT01066494Phase 2
- Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.TerminatedNCT01066468Phase 1
- Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal KaryotypeStatus unknownNCT01066338
- Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid LeukemiaStatus unknownNCT01066286
- The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid LeukemiaWithdrawnNCT01065545Phase 1
- Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)CompletedNCT01063660Phase 2
- S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid LeukemiaCompletedNCT01059734
- Studying Biomarkers in Cell Samples From Patients With Acute Myeloid LeukemiaCompletedNCT01057199
- Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesCompletedNCT01056614Phase 2
- A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT01055483Phase 1
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid LeukemiaCompletedNCT01050036Not applicable
- Targeted, Dose-Escalation Busulfan-Etoposide as Prep RegimenCompletedNCT01048827Phase 1
- Symptom Burden in Chronic Myeloid Leukemia (CML)Status unknownNCT01046305
- MSC and HSC Coinfusion in Mismatched MinitransplantsTerminatedNCT01045382Phase 2
- Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid LeukemiaStatus unknownNCT01039363Phase 2
- PR104 in Treating Patients With Refractory/Relapsed Acute LeukemiaStatus unknownNCT01037556Phase 1/2
- A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid LeukaemiaCompletedNCT01035502Phase 2
- High-dose Cytarabine and Survival in AMLCompletedNCT01034839